Table 2.
Change in fluid volume status in the SGLT2 inhibitor-treated patients with and without diuretic.
| SGLT2i (n = 53) | SGLT2i + Diuretic (n = 23) | Comparison of Changes | |||||
|---|---|---|---|---|---|---|---|
| Baseline Mean (SD) |
6 Months Mean (SD) |
Change [95% CI] | Baseline Mean (SD) |
6 Months Mean (SD) |
Change [95% CI] | p Value | |
| ePV, L | 2.66 (0.53) | 2.51 (0.06) | −0.10 [−0.15 to −0.06] | 2.75 (0.46) | 2.58 (0.41) | −0.16 [−0.24 to −0.08] | 0.0908 |
| IF, L | 11.22 (2.83) | 10.83 (2.90) | −0.19 [−0.37 to −0.06] | 11.42 (2.26) | 10.62 (2.38) | −1.02 [−1.67 to −0.37] | 0.0007 |
| ECW, L | 13.62 (3.30) | 13.27 (3.12) | −0.23 [−0.48 to 0.03] | 14.17 (2.53) | 13.21 (2.57) | −1.16 [−1.80 to −0.53] | 0.0006 |
| ICW, L | 21.15 (5.06) | 20.62 (5.01) | −0.39 [−0.74 to −0.05] | 20.33 (3.93) | 19.30 (4.67) | −1.03 [−1.75 to −0.32] | 0.0332 |
| TBW, L | 34.77 (8.33) | 33.89 (8.09) | −0.62 [−1.19 to −0.05] | 34.49 (6.34) | 32.90 (6.93) | −2.05 [−3.35 to −0.74] | 0.0096 |
| ECW/TBW | 0.393 (0.010) | 0.393 (0.002) | 0.001 [−0.002 to 0.004] | 0.411 (0.018) | 0.403 (0.003) | −0.009 [−0.013 to −0.005] | 0.0003 |
A t-test was performed on the change between the SGLT-2i group and SGLT-2i+diuretic group and a p-value was caliculated. Data are presented as mean (standard deviation). ePV, estimated plasma volume; ECW, extracellular water; TBW, total body water; ICW, intracellular water; IF, interstitial fluid. SGLT2i, SGLT2 inhibitor dapagliflozin; SGLT2i + diuretic, dapagliflozin and diuretics (loop or thiazide diuretic); SD, standard deviation; 95% CI, 95% confidence interval.